Rossari Biotech Q2 & H1 FY27 Earnings Presentation Released
Rossari Biotech reported record Q2 FY27 revenue of ₹698 crore (19% YoY growth) and H1 FY27 revenue of ₹1,395 crore (23% YoY growth). The company's Board approved leasing land for a greenfield manufacturing facility in Saudi Arabia. Q2 FY27 EBITDA was ₹87 crore (20.9% YoY growth), and PAT was ₹38.9 crore. Net debt reduced to ₹221 crore.
The announcement includes strong financial performance with record revenues and EBITDA, a strategic expansion into Saudi Arabia, and a reduction in debt, all of which are material factors for investors and indicate significant company development.
The company reported record quarterly revenue and EBITDA, alongside significant year-on-year growth in both Q2 and H1 FY27. The approval for a new international manufacturing facility and reduction in net debt further contribute to a positive outlook.
Rossari Biotech Limited has released its Earnings Presentation for the quarter and half-year ended September 30, 2026.
The company reported robust consolidated growth of 19% year-on-year in Q2 FY27, achieving a record quarterly revenue of ₹698 crore. For the first half of FY27, consolidated revenue stood at ₹1,395 crore, a 23% year-on-year growth. The performance was driven by healthy domestic momentum and international expansion.
Key business updates include the Board's approval for leasing land to its wholly-owned subsidiary, Rossari International Limited Company (RILC), for a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This marks a significant milestone in the company's international growth strategy.
In Q2 FY27, the company achieved its highest-ever quarterly revenue of ₹697.6 crore and highest-ever quarterly EBITDA of ₹87.0 crore, representing 19.0% and 20.9% year-on-year growth, respectively. Profit After Tax was ₹38.9 crore. Export sales reached a record high of ₹216.4 crore, a 33.8% year-on-year growth. The net working capital cycle improved to 86 days as of September 30, 2026, and net debt declined to ₹221 crore from ₹281 crore as of March 31, 2026.
The Home, Personal Care and Performance Chemicals (HPPC) business grew 18% YoY, Textile Specialty Chemicals (TSC) grew 26% YoY, and Animal Health and Nutrition (AHN) grew 11% YoY. The company also commissioned one of India’s largest EO storage facilities at its Unitop site.
What to do with a filing like this
Rossari Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rossari Biotech Limited. Read the original for the full detail.